Phenobarbital pharmacokinetics in old age: A case-matched evaluation based on therapeutic drug monitoring data

Epilepsia

Volumn 46, Issue 3, 2005, Pages 372-377

  Messina, Sara ^a   Battino, Dina ^a   Croci, Danilo ^a   Mamoli, Daniela ^a   Ratti, Sara ^a   Perucca, Emilio ^b,c  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Elderly; Epilepsy; Pharmacokinetics; Phenobarbital; Therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN;

AGED; AGING; ARTICLE; BODY WEIGHT; CALCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG MONITORING; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SENESCENCE; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ALGORITHMS; ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PHENOBARBITAL; REGRESSION ANALYSIS;

EID: 14944339252     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2005.47504.x     Document Type: Article

References (32)

1. Stephen LJ, Brodie MJ. Epilepsy in elderly people. Lancet 2000;355:1441-6.
2. Faught E. Epidemiology and drug treatment of epilepsy in elderly people. Drugs Aging 1999;15:255-69.
3. Willmore LJ. The effect of age on pharmacokinetics of antiepileptic drugs. Epilepsia 1995;36:S14-21.
4. Bernus I, Dickinson RG, Hooper WD, Eadie MJ. Anticonvulsant therapy in aged patients: clinical pharmacokinetic considerations. Drugs Aging 1997;10:278-89.
5. Tallis R, Boon P, Perucca E, Stephen L. Epilepsy in elderly people: management issues. Epileptic Disord 2002;4:S33-9.
6. Lackner TE, Cloyd JC, Thomas LW, et al. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia 1998;39:1083-7.
7. Schachter SC, Cramer GW, Thompson GD, et al. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc 1998;46:1137-41.
8. Baldy-Moulinier M, Covanis A, D'Urso S, et al. Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. Seizure 1998;7:513-20.
9. Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia 2004;45:1141-9.
10. Kale R, Perucca E. Revisiting phenobarbital for epilepsy. BMJ 2004 (in press).
11. Pugh MJ, Cramer J, Knoefel J, et al. Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. J Am Geriatr Soc 2004;52:417-22.
12. Cloyd JC, Lackner TE, Leppik IE. Antiepileptics in the elderly: pharmacoepidemiology and pharmacokinetics. Arch Fam Med 1994;3:589-98.
13. Galimberti CA. Issues in nursing home settings. Epilepsia 2003;44(suppl 8):23.
14. Parker BM, Cusack BJ, Vestal RE. Pharmacokinetic optimisation of drug therapy in elderly patients. Drugs Aging 1995;7:10-8.
15. Leppik IE. Epilepsy in the elderly. Curr Neurol Neurosci Rep 2001;1:396-402.
16. King-Stephens D. The treatment of epilepsy in the elderly. CNS Drugs 1999;12:21-33.
17. Anderson GD. Phenobarbital and other barbiturates: chemistry, biotransformation and pharmacokinetics. In: Levy R, Mattson R, Mieldrum B, et al., eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:496-503.
18. Battino D, Croci D, Rossini A, et al. Serum carbamazepine concentrations in elderly patients: a case-matched pharmacokinetic evaluation based on therapeutic drug monitoring data. Epilepsia 2003;44:923-9.
19. Battino D, Croci D, Mamoli D, et al. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data. Epilepsy Res 2004;59:155-65.
20. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet 1995;29:257-86.
21. Eadie MJ, Lander CM, Hooper WD, et al. Factors influencing plasma phenobarbitone levels in epileptic patients. Br J Clin Pharmacol 1977;4:541-7.
22. Martines C, Gatti G, Sasso E, et al. The disposition of primidone in elderly patients. Br J Clin Pharmacol 1990;30:607-11.
23. Windorfer A Jr, Sauer W. Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbitone, clonazepam, nitrazepam, carbamazepin and dipropylacetate. Neuropadiatrie 1977;8:29-41.
24. Lambie DG, Johnson RH. The effects of phenytoin on phenobarbitone and primidone metabolism. J Neurol Neurosurg Psychiatry 1981;44:148-51.
25. Callaghan N, Feely M, Duggan F, et al. The effect of anticonvulsant drugs which induce liver microsomal enzymes on derived and ingested phenobarbitone levels. Acta Neurol Scand 1977;56:1-6.
26. Boyd RA, Turck D, Abel RB, et al. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia 1999;40:474-9.
27. Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 2003;25:123-9.
28. Haegele KD, Huebert ND, Ebel M, et al. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clin Pharmacol Ther 1988;44:558-65.
29. Graves NM, Brundage RC, Wen Y, et al. Population pharmacokinetics of carbamazepine in adults with epilepsy. Pharmacotherapy 1998;18:273-81.
30. Perucca E, Grimaldi R, Gatti G, et al. Pharmacokinetics of valproic acid in the elderly. Br J Clin Pharmacol 1984;17:665-9.
31. Bauer LA, Davis R, Wilensky A, et al. Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults. Clin Pharmacol Ther 1985;37:697-700.
32. Bachmann KA, Belloto RJ Jr. Differential kinetics of phenytoin in elderly patients. Drugs Aging 1999;15:235-50.